Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
This trial is a multicentric study aiming to assess the evolution of the serum ifosfamide
concentrations and its serum metabolites in patients treated for an Soft Tissue Sarcoma and
co-exposed to Aprepitant.
The study will be conducted on a population of patients treated with Doxorubicin and
Ifosfamide. The Aprepitant can be prescribed to patients from cycle 2, according to the
current recommendations. Doxorubicin, Ifosfamide and Aprepitant will be administered in the
context of routine care. The follow-up during the treatment period and the clinical,
biological and radiological assessments will be performed according to the standard of each
centre.
Patients will be followed during the two first cycles of treatment. For the pharmacokinetic
study, blood samples will be collected at different time points during the 2 treatment
cycles.